Online Inquiry


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Animal Models for Cancer Vaccine

Vaccine. For tumor vaccines, traditional animal models for toxicity evaluation usually provide limited information, especially for human-specific antigens targeted. Creative Biolabs is dedicated to establishing the most suitable animal models for cancer vaccine development including pre-clinical pharmacology services and pre-clinical toxicology services. Our animal models are ready to be directly delivered to your institute or conducted outsourcing pharmacology and toxicology studies with our own facilities.

Animal Models

Careful selection of animal models is critical for drug-sensitive species and toxicological studies of cancer vaccines according to the anticipated clinical route of administration. With superior commercial breeding facilities, rigorous biosecurity and genetic standards, and relative research support services, we can provide cancer vaccine developers with specific animal models to best meet your discovery and development needs. Our animal models include:

How to Choose Animal Models

  1. To select animal species for toxicity testing, it should be based on the expression and homology of the target antigens. Animal models expressing the targeted Ag or epitope of interest, if any, are more likely to reveal the effects of Ag “sinks” or tissues with unexpected Ag expression on tissue localization and/or toxicity in biological distribution.
  2. For pre-clinical trials of vaccine, immunocompetent mice models are necessary such as syngeneic model and humanized model. In addition, for xenograft models, if the relevant human receptor or protein are not expressed, transgenic models are applied such as the expression of appropriate human HLA molecule for immune responsiveness, or we can evaluate the effect of therapy on human protein homologues in animals.
  3. For solid malignant tumors, we recommend solid tumor xenograft rather than tumor cell line administered to animals since PDX may mimic human disease.
  4. For GT vector-based vaccines, we will offer studies to evaluate tissue biodistribution and persistence. especially in reproductive tissues. Gene expression and pathological changes will be designed and conducted when abnormal or unexpected localization is observed. In addition, autoimmune reactions and inflammatory response will also be detected.

Related Capabilities

Animal model species

• Small animal models: Mouse (disease state, normal or immunode ficient), Rat (normal or immunodeficient), Guinea, Pig, Rabbit;

• Large animal models: Dog, Pig, Mini-pig, Goat Sheep, Non-human primate

Routes of administration

• Intravenous, Intra-arterial, Intradermal, Intramuscular, Subcutaneous, Oral Intraperitoneal, Intraportal

Accelerate Discovery of Vaccine Delivery, Immunopathogenesis and Immune Response to Vaccination!

Purposes in Using Animal Models

  1. Proof-of-concept testing: Immunogenicity, Challenge studies;
  2. Safety testing: Toxicity testing (inactivated vaccines), Viral safety testing (live-attenuated vaccines), Batch-release testing;
  3. Quality testing: Adventitious agents.

We understand that selecting the most appropriate animal model for your cancer vaccine development is critical to ultimate success. Creative Biolabs is dedicated to providing you with high-quality animal models, including mice, rabbits, guinea pigs, etc. to maximize the success of your programs. We are committed to helping you through the in vivo assessments through our excellent assays. Please contact us for further information.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.